Ryzodeg 70/30 market seen growing through 2030
The market for Ryzodeg 70/30 is expanding as diabetes rates rise, populations age and healthcare spending increases. North America led the market in 2025, while Asia-Pacific is expected to grow the fastest in the coming years.
Why it matters: - Ryzodeg 70/30 is benefiting from rising global diabetes cases, a larger elderly population and broader use of insulin therapies. - The combination insulin is positioned for patients who need both rapid and long-acting glucose control. - Demand is also being supported by more home-based diabetes management and digital monitoring tools.
What happened: - The Business Research Company released its Ryzodeg 70/30 Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says the market is gaining traction across major regions and expects continued growth through 2030 and beyond. - The report’s sample can be accessed here.
The details: - Ryzodeg 70/30 combines 70% insulin degludec and 30% insulin aspart. - The therapy is designed to provide both immediate and sustained insulin effects for people with type 1 or type 2 diabetes. - Historic market growth has been linked to higher rates of type 1 and type 2 diabetes, wider adoption of insulin therapy, better diagnosis of chronic diabetes cases, growth in hospital-based diabetes care and the availability of combination insulin products. - Future growth is expected to come from demand for more convenient insulin therapies, innovation in long-acting insulin, increased home-based diabetes management, higher healthcare spending on chronic disease and digital diabetes monitoring. - Key trends include more use of fixed-ratio combination insulins, preference for long-acting basal-bolus therapies, simplified treatment regimens, expansion of pen-based insulin delivery systems and greater focus on glycemic stability. - The report identifies rising diabetes prevalence as a major growth driver. - The report cites the UK’s Office for Health Improvement and Disparities showing that between March 2022 and March 2023, the share of people with type 1 diabetes receiving all eight recommended care processes rose 22%, while the share for type 2 diabetes rose 21%. - The same data set showed the proportion of patients reaching target HbA1c levels increased to 37.9%. - The report also points to aging populations as a growth catalyst. - The Population Reference Bureau projected in January 2024 that Americans aged 65 and older will rise 47%, from 58 million in 2022 to 82 million by 2050. - That age group’s share of the US population is expected to increase from 17% to 23%. - Higher healthcare spending is another supporting factor. - The US Centers for Medicare & Medicaid Services reported in December 2024 that US healthcare spending rose 7.5% in 2023 to $4.9 trillion, or about $14,570 per person. - In 2025, North America was the largest regional market for Ryzodeg 70/30. - Asia-Pacific is forecast to be the fastest-growing region in the coming years. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa.
Between the lines: - The market thesis is straightforward: more diabetes, older populations and more treatment access tend to expand demand for insulin products that simplify management. - The emphasis on convenience, pen delivery and digital monitoring suggests the market is shifting toward treatment models that reduce day-to-day burden for patients and caregivers. - The report frames Ryzodeg 70/30 as part of a broader move toward combination therapies that aim to improve adherence and glucose stability.
What's next: - The Business Research Company says its 2026 report update adds market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel forecasting dashboards, market hotspot infographics, and updated graphics and tables. - The firm also highlights future trend analysis and key technology coverage as part of the new release. - More information is available on the company’s website.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
UK Post Observer
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.